Synonym
Binifibrate; WAC-104; WAC 104; WAC104; Biniwas; Antopal
IUPAC/Chemical Name
4-(2-(4-chlorophenoxy)-3-((3-((2,3-dihydroxypropoxy)carbonyl)pyridin-4-yl)oxy)-2-methyl-3-oxopropyl)nicotinate
InChi Key
USIXGWMVXQSJBA-UHFFFAOYSA-M
InChi Code
InChI=1S/C25H23ClN2O9/c1-25(37-18-4-2-16(26)3-5-18,10-15-6-8-27-11-19(15)22(31)32)24(34)36-21-7-9-28-12-20(21)23(33)35-14-17(30)13-29/h2-9,11-12,17,29-30H,10,13-14H2,1H3,(H,31,32)/p-1
SMILES Code
CC(CC1=CC=NC=C1C([O-])=O)(OC2=CC=C(Cl)C=C2)C(OC3=CC=NC=C3C(OCC(CO)O)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
529.91
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Corominas Vilardell A, de Oya Otero M, Escobar Jiménez F, Anguera Vila A, Ariño Armengol B. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia]. An Med Interna. 1993 Nov;10(11):537-41. Spanish. PubMed PMID: 8117868.
2: Avellaneda A, Rueda A, Cascio C, Gutiérrez JA. [Changes in the lipid profiles of hyperlipemic patients treated with binifibrate]. An Med Interna. 1993 Jun;10(6):275-9. Spanish. PubMed PMID: 8334204.
3: Sánchez-Torres JM, Pedraz JL, Gascón AR, Begoña Calvo M, Hernández RM, Domínguez-Gil A. Biotransformation kinetic of binifibrate and identification of its metabolites. Boll Chim Farm. 1991 May;130(5):172-7. PubMed PMID: 1760151.
4: Dalmau M, Monasterio J, Nogués R, Picó M, Freixes J, Bruseghini L, Diez S, Andreoli R. Microhaemorheological properties of binifibrate. Part II: Preliminary open studies in patients with peripheral arteriopathies. Arzneimittelforschung. 1983;33(6):858-61. PubMed PMID: 6684440.
5: Bruseghini L, Freixes J, Andreoli R. Microhaemorheological properties of binifibrate. Part I: Experimental studies. Arzneimittelforschung. 1983;33(6):854-7. PubMed PMID: 6684439.
6: Labiós Gómez M, Romero Simo M, Gabriel Botella F, Martín Valles H, Morera Llorca M, Freixas Ventura J. [Changes in blood viscosity and erythrocyte deformability in patients with dyslipidemia treated with binifibrate]. An Med Interna. 1990 Oct;7(10):517-21. Spanish. PubMed PMID: 2104097.
7: Carr JF, Lee HJ, Jaspers JB, Dahlberg AE, Jogl G, Gregory ST. Phenotypic Suppression of Streptomycin Resistance by Mutations in Multiple Components of the Translation Apparatus. J Bacteriol. 2015 Sep;197(18):2981-8. doi: 10.1128/JB.00219-15. PubMed PMID: 26148717; PubMed Central PMCID: PMC4542173.
8: Labios M, Martínez M, Vayá A, Gabriel F, Guiral V, Aznar J. Effect of a modified fibrate (Biniwas Retard) on hemorheological alterations in hyperlipemic patients. Clin Hemorheol Microcirc. 1999;21(2):79-85. PubMed PMID: 10599590.
